ArticleMedical care2016

Estimating the Population Benefits and Costs of Rituximab Therapy in the United States from 1998 to 2013 Using Real-World Data.

Mark D Danese et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.